Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.22
-0.29 (-2.76%)
At close: Jul 24, 2026, 4:00 PM EDT
10.25
+0.03 (0.29%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 122.47% growth.
Revenue (ttm)
$803.79M
Revenue Growth
+55.61%
P/S Ratio
4.33
Revenue / Employee
$678,880
Employees
1,184
Market Cap
3.48B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.24% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.88% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcutis Biotherapeutics | 415.62M |
| Arcus Biosciences | 236.00M |
| IDEAYA Biosciences | 225.27M |
| Tango Therapeutics | 56.99M |
| NewAmsterdam Pharma Company | 22.57M |
| Alumis | 8.40M |
TLX News
- 3 days ago - TLX591-Tx ProstACT SELECT Study Published in Cancers Journal - GlobeNewsWire
- 3 days ago - Telix Pharma Q2 Revenue Rises 21%; Doses First Patient In Phase 3 LUTEON Trial; Shares Jump - Nasdaq
- 3 days ago - Telix Pharmaceuticals (TLX) Reports Strong Q2 Revenue Growth and Upbeat FY 2026 Outlook - GuruFocus
- 4 days ago - Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business - Nasdaq
- 4 days ago - Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewsWire
- 4 days ago - Telix Pharmaceuticals Earnings release: Q2 2026 - Filings
- 4 days ago - Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer - GlobeNewsWire
- 8 days ago - Telix Opens Australian GMP Facility; Doses First Patient In Phase 2 Prostate Cancer Trial - Nasdaq